TY - JOUR
T1 - Controversies in Drug Allergy: Drug Allergy Pathways
AU - Chiriac, Anca M.
AU - Banerji, Aleena
AU - Gruchalla, Rebecca S.
AU - Thong, Bernard Y. H.
AU - Wickner, Paige
AU - Mertes, Paul-Michel
AU - Terreehorst, Ingrid
AU - Blumenthal, Kimberly G.
N1 - Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
PY - 2019/1
Y1 - 2019/1
N2 - Drug allergy pathways are standardized approaches for patients reporting prior drug allergies with the aim of quality improvement and promotion of antibiotic stewardship. At the International Drug Allergy Symposium during the 2018 American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress in Orlando, Florida, drug allergy pathways were discussed from international perspectives with a focus on beta-lactam allergy pathways and pragmatic approaches for acute care hospitals. In this expert consensus document, we review current pathways, and detail important considerations in devising, implementing, and evaluating beta-lactam allergy pathways for hospitalized patients. We describe the key patient and institutional factors that must be considered in risk stratification, the central feature of pathway design. We detail shared obstacles to widespread beta-lactam allergy pathway implementation and identify potential solutions to address these challenges.
AB - Drug allergy pathways are standardized approaches for patients reporting prior drug allergies with the aim of quality improvement and promotion of antibiotic stewardship. At the International Drug Allergy Symposium during the 2018 American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress in Orlando, Florida, drug allergy pathways were discussed from international perspectives with a focus on beta-lactam allergy pathways and pragmatic approaches for acute care hospitals. In this expert consensus document, we review current pathways, and detail important considerations in devising, implementing, and evaluating beta-lactam allergy pathways for hospitalized patients. We describe the key patient and institutional factors that must be considered in risk stratification, the central feature of pathway design. We detail shared obstacles to widespread beta-lactam allergy pathway implementation and identify potential solutions to address these challenges.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85058940079&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30573422
U2 - https://doi.org/10.1016/j.jaip.2018.07.037
DO - https://doi.org/10.1016/j.jaip.2018.07.037
M3 - Review article
C2 - 30573422
SN - 2213-2201
VL - 7
SP - 46-60.e4
JO - journal of allergy and clinical immunology. In practice
JF - journal of allergy and clinical immunology. In practice
IS - 1
ER -